Catalent To Sell Somerset NJ Oral Solids Facility to CDMO Ardena
Catalent has agreed to sell its oral solids development and small-scale manufacturing facility in Somerset, New Jersey, to Ardena, a Ghent, Belgium-based CDMO of drug substances and drug products.
The decision to sell these assets comes amid Novo Holdings pending $16.5-billion acquisition of Catalent, a deal which is expected to close later this year (2024). After closing, Novo Holdings, the parent company of Novo Nordisk, plans to sell three three fill–finish facilities to Novo Nordisk for $11 billion to provide manufacturing capacity for Novo’s diabetes and obesity drugs.
The Somerset facility also houses Catalent’s corporate headquarters, which in the near term will remain at the Somerset site during a transition period before shifting to a new location.
The sale of the oral solid dosage assets from Catalent to Ardena is expected to close in early 2025, subject to regulatory approvals and other customary closing conditions.
Ardena has five development and manufacturing facilities in Europe (Belgium, the Netherlands, Spain and Sweden). The pending facility acquisition from Catalent will add US-based capabilities for Ardena.
